Prof. Huiyan Luo 骆卉妍
Chief Physician, Professor
Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Medical oncology for gastrointestinal cancers, including esophageal, gastric, colorectal, pancreatic, and liver cancer. Focuses on chemotherapy, targeted therapy, drug resistance, and liquid biopsy applications.
Dr. Luo earned a clinical medicine degree from Guangxi Medical University (2000) and a master’s in oncology from Sun Yat-sen University Cancer Center (2007). After specialty training and serving as an attending physician while earning a PhD, Dr. Luo was a visiting scholar at the University of California, San Diego (2015–2017). Currently an associate chief physician at Sun Yat-sen University Cancer Center.
Professional roles
- Member, China Anti-Cancer Association
- Member, Guangdong Anti-Cancer Association
Name order: in Chinese the family name comes first (Luo Huiyan). Papers usually list the name as Huiyan Luo or Luo H.
Selected publications
134 papers on PubMed matched by name and affiliation; 22 as first or senior author since 2016. Most recent first- or senior-author papers:
- iScience, 2026 (senior author): A biomarker analysis of plasma RIME and PD-L1 for stratifying first-line immunochemotherapy outcomes in advanced ESCC. PubMed 42964759
- Cancer Discov, 2026 (senior author): Longitudinal Plasma Metabolomics Guides Dynamic Risk Assessment and Dietary Modulation for Esophageal Squamous Cell Cancer Chemoimmunotherapy. PubMed 41771153
- Oncogene, 2026 (senior author): Targeted methylation of cg24067911 suppresses colorectal cancer metastasis through BCL6-ATXN1-CDH1 axis. PubMed 41326664
- Cancer Commun (Lond), 2025 (first author): The INSPECTOR study: enhanced feasibility for clinical translation of a multi-cancer early detection method based on enzyme-assisted high signal-to-noise ratio sequencing of methylated circulating tumor DNA. PubMed 41165038
- MedComm (2020), 2025 (senior author): Blood Microbiome Reveals the Impact of Lactobacillus on the Efficacy of Immunotherapy in Gastrointestinal Cancer. PubMed 40791867
- Cancer Cell, 2025 (first author): Global alliances in translational cancer research. PubMed 40020671
- Gut, 2025 (senior author): CAF-macrophage crosstalk in tumour microenvironments governs the response to immune checkpoint blockade in gastric cancer peritoneal metastases. PubMed 39537239
- Signal Transduct Target Ther, 2024 (senior author): Addition of SHR-1701 to first-line capecitabine and oxaliplatin (XELOX) plus bevacizumab for unresectable metastatic colorectal cancer. PubMed 39676137
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion